Echocardiography combined with Mayo staging enhances the identification of early mortality risk in patients with light-chain cardiac amyloidosis
Author:
Publisher
Science China Press., Co. Ltd.
Subject
Multidisciplinary
Link
https://engine.scichina.com/doi/pdf/2F1FE2A7A9944FB6B95BBC12809DBF54
Reference22 articles.
1. Kastritis E, Leleu X, Arnulf B. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol, 2020, 38: 3252-3260.
2. Wechalekar A D, Sanchorawala V. Daratumumab in AL amyloidosis. Blood, 2022, 140: 2317-2322.
3. Shen K N, Zhang C L, Tian Z. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: A retrospective case control study. Amyloid, 2019, 26: 66-73.
4. Muchtar E, Gertz M A, Kumar S K. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: Cracking the glass ceiling of early death. Blood, 2017, 129: 2111-2119.
5. Wechalekar A D, Schonland S O, Kastritis E. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121: 3420-3427.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3